Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Veterinary API Manufacturing Market

ID: MRFR/Pharma/39235-HCR
100 Pages
Rahul Gotadki
Last Updated: April 15, 2026
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Research Report By API Type (Antibiotics, Anti-Infectives, Anti-Inflammatories, Parasiticides, Hormones), By Dosage Form (Oral, Injectable, Topical, Ophthalmic, Intramammary), By Animal Type (Companion Animals (Dogs, Cats), Farm Animals (Cattle, Swine, Poultry), Aquaculture Animals (Fish, Shrimp)), By Therapeutic Area (Antibacterial, Antiviral, Antifungal, Antiparasitic, Cardiovascular) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY API Type (USD Billion) | |
      1. 4.1.1 Antibiotics | |
      2. 4.1.2 Anti-Infectives | |
      3. 4.1.3 Anti-Inflammatories | |
      4. 4.1.4 Parasiticides | |
      5. 4.1.5 Hormones |
    2. 4.2 Healthcare, BY Dosage Form (USD Billion) | |
      1. 4.2.1 Oral | |
      2. 4.2.2 Injectable | |
      3. 4.2.3 Topical | |
      4. 4.2.4 Ophthalmic | |
      5. 4.2.5 Intramammary |
    3. 4.3 Healthcare, BY Animal Type (USD Billion) | |
      1. 4.3.1 Companion Animals | |
      2. 4.3.2 Farm Animals | |
      3. 4.3.3 Aquaculture Animals |
    4. 4.4 Healthcare, BY Therapeutic Area (USD Billion) | |
      1. 4.4.1 Antibacterial | |
      2. 4.4.2 Antiviral | |
      3. 4.4.3 Antifungal | |
      4. 4.4.4 Antiparasitic | |
      5. 4.4.5 Cardiovascular |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Boehringer Ingelheim (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Zoetis (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Merck Animal Health (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Elanco Animal Health (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 BASF (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Virbac (FR) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Ceva Santé Animale (FR) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Heska Corporation (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Dechra Pharmaceuticals (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY API TYPE |
    7. 6.4 US MARKET ANALYSIS BY DOSAGE FORM |
    8. 6.5 US MARKET ANALYSIS BY ANIMAL TYPE |
    9. 6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA |
    10. 6.7 CANADA MARKET ANALYSIS BY API TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DOSAGE FORM |
    12. 6.9 CANADA MARKET ANALYSIS BY ANIMAL TYPE |
    13. 6.10 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY API TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY DOSAGE FORM |
    17. 6.14 GERMANY MARKET ANALYSIS BY ANIMAL TYPE |
    18. 6.15 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
    19. 6.16 UK MARKET ANALYSIS BY API TYPE |
    20. 6.17 UK MARKET ANALYSIS BY DOSAGE FORM |
    21. 6.18 UK MARKET ANALYSIS BY ANIMAL TYPE |
    22. 6.19 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
    23. 6.20 FRANCE MARKET ANALYSIS BY API TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY DOSAGE FORM |
    25. 6.22 FRANCE MARKET ANALYSIS BY ANIMAL TYPE |
    26. 6.23 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
    27. 6.24 RUSSIA MARKET ANALYSIS BY API TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DOSAGE FORM |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    31. 6.28 ITALY MARKET ANALYSIS BY API TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY DOSAGE FORM |
    33. 6.30 ITALY MARKET ANALYSIS BY ANIMAL TYPE |
    34. 6.31 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
    35. 6.32 SPAIN MARKET ANALYSIS BY API TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY DOSAGE FORM |
    37. 6.34 SPAIN MARKET ANALYSIS BY ANIMAL TYPE |
    38. 6.35 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY API TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY API TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY DOSAGE FORM |
    46. 6.43 CHINA MARKET ANALYSIS BY ANIMAL TYPE |
    47. 6.44 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    48. 6.45 INDIA MARKET ANALYSIS BY API TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY DOSAGE FORM |
    50. 6.47 INDIA MARKET ANALYSIS BY ANIMAL TYPE |
    51. 6.48 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    52. 6.49 JAPAN MARKET ANALYSIS BY API TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY DOSAGE FORM |
    54. 6.51 JAPAN MARKET ANALYSIS BY ANIMAL TYPE |
    55. 6.52 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY API TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY API TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    64. 6.61 THAILAND MARKET ANALYSIS BY API TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY DOSAGE FORM |
    66. 6.63 THAILAND MARKET ANALYSIS BY ANIMAL TYPE |
    67. 6.64 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
    68. 6.65 INDONESIA MARKET ANALYSIS BY API TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DOSAGE FORM |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY API TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY API TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DOSAGE FORM |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
    81. 6.78 MEXICO MARKET ANALYSIS BY API TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY DOSAGE FORM |
    83. 6.80 MEXICO MARKET ANALYSIS BY ANIMAL TYPE |
    84. 6.81 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY API TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY API TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY API TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY API TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY API TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY API TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY API TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY API TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DOSAGE FORM, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By API Type (USD Billion, 2025-2035)

  • Antibiotics
  • Anti-Infectives
  • Anti-Inflammatories
  • Parasiticides
  • Hormones

Healthcare By Dosage Form (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Topical
  • Ophthalmic
  • Intramammary

Healthcare By Animal Type (USD Billion, 2025-2035)

  • Companion Animals
  • Farm Animals
  • Aquaculture Animals

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

  • Antibacterial
  • Antiviral
  • Antifungal
  • Antiparasitic
  • Cardiovascular